Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:FULC NASDAQ:ORMP NASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.92+0.8%$6.48$3.93▼$7.54$354.60M1.67994,238 shs209,480 shsFULCFulcrum Therapeutics$7.65+11.2%$7.05$2.32▼$9.30$415.63M2.82571,753 shs357,526 shsORMPOramed Pharmaceuticals$2.22$2.14$1.82▼$3.09$91.02M1.69137,264 shs49,860 shsRCKTRocket Pharmaceuticals$3.25+0.5%$3.10$2.19▼$22.01$349.06M0.623.67 million shs861,589 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-1.29%-0.29%+6.03%+1.78%+23.16%FULCFulcrum Therapeutics+5.52%+3.46%0.00%-5.10%-16.61%ORMPOramed Pharmaceuticals+0.91%+0.91%+6.73%0.00%-6.72%RCKTRocket Pharmaceuticals-2.71%-3.58%+6.25%+5.21%-81.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.92+0.8%$6.48$3.93▼$7.54$354.60M1.67994,238 shs209,480 shsFULCFulcrum Therapeutics$7.65+11.2%$7.05$2.32▼$9.30$415.63M2.82571,753 shs357,526 shsORMPOramed Pharmaceuticals$2.22$2.14$1.82▼$3.09$91.02M1.69137,264 shs49,860 shsRCKTRocket Pharmaceuticals$3.25+0.5%$3.10$2.19▼$22.01$349.06M0.623.67 million shs861,589 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-1.29%-0.29%+6.03%+1.78%+23.16%FULCFulcrum Therapeutics+5.52%+3.46%0.00%-5.10%-16.61%ORMPOramed Pharmaceuticals+0.91%+0.91%+6.73%0.00%-6.72%RCKTRocket Pharmaceuticals-2.71%-3.58%+6.25%+5.21%-81.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 3.00Buy$19.50182.00% UpsideFULCFulcrum Therapeutics 2.63Moderate Buy$7.57-1.04% DownsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ARCKTRocket Pharmaceuticals 2.41Hold$16.73415.67% UpsideCurrent Analyst Ratings BreakdownLatest ORMP, RCKT, FULC, and ABEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $10.008/20/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/18/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/15/2025ABEOAbeona TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$19.00 ➝ $20.008/11/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.008/8/2025RCKTRocket PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$10.00 ➝ $8.007/30/2025FULCFulcrum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$4.00 ➝ $5.007/29/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $12.007/25/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.00 ➝ $10.007/25/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$9.00 ➝ $4.007/24/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $12.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M101.31N/AN/A$1.01 per share6.85FULCFulcrum Therapeutics$80M5.17N/AN/A$4.51 per share1.70ORMPOramed Pharmaceuticals$1.34M67.93N/AN/A$3.61 per share0.61RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M$0.709.88N/AN/AN/A89.05%45.64%11/13/2025 (Estimated)FULCFulcrum Therapeutics-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.35N/AN/AN/AN/A-19.37%-18.28%11/6/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)Latest ORMP, RCKT, FULC, and ABEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ABEOAbeona Therapeutics-$0.39$1.71+$2.10$1.71$21.71 million$0.40 million8/14/2025Q2 2025ORMPOramed Pharmaceuticals-$0.04-$0.05-$0.01$0.31N/AN/A8/7/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57-$0.59-$0.02-$0.62$4.36 millionN/A7/29/2025Q2 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.096.736.65FULCFulcrum TherapeuticsN/A24.4224.42ORMPOramed PharmaceuticalsN/A26.8226.81RCKTRocket Pharmaceuticals0.056.396.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%FULCFulcrum Therapeutics89.83%ORMPOramed Pharmaceuticals12.73%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics6.90%FULCFulcrum Therapeutics7.00%ORMPOramed Pharmaceuticals17.80%RCKTRocket Pharmaceuticals24.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9051.28 million47.74 millionOptionableFULCFulcrum Therapeutics10054.09 million50.31 millionOptionableORMPOramed Pharmaceuticals1041.00 million33.71 millionOptionableRCKTRocket Pharmaceuticals240107.90 million81.19 millionOptionableORMP, RCKT, FULC, and ABEO HeadlinesRecent News About These CompaniesRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 5 at 3:29 AM | americanbankingnews.comMPM Bioimpact LLC Buys 597,706 Shares of Rocket Pharmaceuticals, Inc. $RCKTSeptember 4 at 7:02 AM | marketbeat.comFrazier Life Sciences Management L.P. Sells 400,000 Shares of Rocket Pharmaceuticals, Inc. $RCKTSeptember 4 at 7:00 AM | marketbeat.comRocket Pharmaceuticals, Inc. $RCKT Shares Bought by Baker BROS. Advisors LPSeptember 4 at 6:27 AM | marketbeat.comRussell Investments Group Ltd. Sells 767,219 Shares of Rocket Pharmaceuticals, Inc. $RCKTSeptember 4 at 3:27 AM | marketbeat.com629,749 Shares in Rocket Pharmaceuticals, Inc. $RCKT Acquired by Nantahala Capital Management LLCSeptember 3 at 7:07 AM | marketbeat.comNuveen LLC Makes New Investment in Rocket Pharmaceuticals, Inc. $RCKTSeptember 2 at 3:31 AM | marketbeat.comJump Financial LLC Invests $1.69 Million in Rocket Pharmaceuticals, Inc. $RCKTAugust 30, 2025 | marketbeat.comSynovus Financial Corp Has $1.86 Million Stock Holdings in Rocket Pharmaceuticals, Inc. $RCKTAugust 29, 2025 | marketbeat.comElisabeth Bjork Buys 10,000 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) StockAugust 28, 2025 | insidertrades.comAlphaQuest LLC Increases Holdings in Rocket Pharmaceuticals, Inc. $RCKTAugust 28, 2025 | marketbeat.comRocket Pharmaceuticals CFO Aaron Ondrey resigns to pursue other opportunitiesAugust 25, 2025 | msn.comWellington Management Group LLP Reduces Stock Holdings in Rocket Pharmaceuticals, Inc. $RCKTAugust 25, 2025 | marketbeat.comWilliam Blair Issues Negative Forecast for RCKT EarningsAugust 24, 2025 | marketbeat.comEMA says Rocket Pharmaceuticals withdraws MA application for FanskyaAugust 22, 2025 | msn.comRocket Pharmaceuticals: Good News As Clinical Hold Lifted - But Challenges RemainAugust 22, 2025 | seekingalpha.comRocket Pharmaceuticals (RCKT) Receives a Sell from Goldman SachsAugust 22, 2025 | theglobeandmail.comRCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease StudyAugust 21, 2025 | zacks.comRocket Pharmaceuticals announces clinical hold lifted on RP-A501 trialAugust 20, 2025 | msn.comJohn Militello Sells 7,043 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) StockAugust 20, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider Sells $33,706.22 in StockAugust 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORMP, RCKT, FULC, and ABEO Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$6.92 +0.06 (+0.80%) As of 01:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Fulcrum Therapeutics NASDAQ:FULC$7.67 +0.79 (+11.42%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Oramed Pharmaceuticals NASDAQ:ORMP$2.22 0.00 (0.00%) As of 01:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Rocket Pharmaceuticals NASDAQ:RCKT$3.24 +0.02 (+0.46%) As of 01:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
